(Q37474070)

English

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

scientific article published on 13 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

1 reference

based on heuristic

inferred from title

Ursula A. Matulonis

1

object named as

Ursula A Matulonis

1 reference

Europe PubMed Central

20 August 2017

author name string

Suzanne Berlin

2

1 reference

Europe PubMed Central

20 August 2017

Percy Ivy

3

1 reference

Europe PubMed Central

20 August 2017

Karin Tyburski

4

1 reference

Europe PubMed Central

20 August 2017

Carolyn Krasner

5

1 reference

Europe PubMed Central

20 August 2017

Corrine Zarwan

6

1 reference

Europe PubMed Central

20 August 2017

Anna Berkenblit

7

1 reference

Europe PubMed Central

20 August 2017

Susana Campos

8

1 reference

Europe PubMed Central

20 August 2017

Neil Horowitz

9

1 reference

Europe PubMed Central

20 August 2017

Stephen A Cannistra

10

1 reference

Europe PubMed Central

20 August 2017

Hang Lee

11

1 reference

Europe PubMed Central

20 August 2017

Julie Lee

12

1 reference

Europe PubMed Central

20 August 2017

Maria Roche

13

1 reference

Europe PubMed Central

20 August 2017

Margaret Hill

14

1 reference

Europe PubMed Central

20 August 2017

Christin Whalen

15

1 reference

Europe PubMed Central

20 August 2017

Laura Sullivan

16

1 reference

Europe PubMed Central

20 August 2017

Chau Tran

17

1 reference

Europe PubMed Central

20 August 2017

Benjamin D Humphreys

18

1 reference

Europe PubMed Central

20 August 2017

Richard T Penson

19

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

13 October 2009

1 reference

Europe PubMed Central

20 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

20 August 2017

27

1 reference

Europe PubMed Central

20 August 2017

33

1 reference

Europe PubMed Central

20 August 2017

5601-5606

1 reference

Europe PubMed Central

20 August 2017

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Tumor angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Vascular endothelial growth factor signaling pathways: therapeutic perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

The biology of VEGF and its receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

23 August 2017

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

14 September 2017

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

28 September 2017

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

2 September 2018

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

2 September 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

2 September 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

2 September 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792954

2 September 2018

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826113

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19826113

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.23.2777

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37474070&oldid=2046310473"